WuXi ATU and Wugen Announce Manufacturing Partnership to Expedite the Delivery of Novel Cell Cancer Immunotherapies

Jun 15, 2022

PHILADELPHIA and ST. LOUIS, MO and SAN DIEGO, June 15, 2022 /PRNewswire/ — WuXi Advanced Therapies (WuXi ATU), a global Contract Testing, Development and Manufacturing Organization (CTDMO), and Wugen Inc., a clinical-stage biotechnology company based in St....

WuXi Advanced Therapies’ GMP plasmid manufacturing and testing facility in Wuxi City passes EU Qualified Person Audit

Apr 28, 2022

WuXi Advanced Therapies (WuXi ATU) announced that it has successfully passed the European Union (EU) Qualified Person (QP) Audit and received the QP Statement supporting the facility in Wuxi City, China. This audit verifies that WuXi ATU’s Wuxi City site has...

WuXi Advanced Therapies and A*STAR announce partnership to advance cell and gene therapy in the Asia-Pacific region

Apr 28, 2022

28 April 2022 – SINGAPORE. WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, and A*STAR’s Bioprocessing Technology Institute (BTI), announced a new partnership to bring WuXi ATU’s proprietary Tetracycline-Enabled Self-Silencing Adenovirus...

Chimeric enters strategic manufacturing partnership with WuXi Advanced Therapies

Apr 11, 2022

Chimeric Therapeutics will leverage WuXi Advanced Therapies’ (“WuXi ATU”) closed loop CAR T platform and other capabilities to accelerate the clinical development of their CHM 1101 (CLTX CAR T) and CHM 2101 (CDH17 CAR T) programs for glioblastoma and gastrointestinal...

WuXi ATU Announces Launch of TESSA™ Technology to Improve Scalability and Accessibility of Cell and Gene Therapies

Mar 8, 2022

TESSA™ technology provides a scalable process for manufacturing gene therapies, accelerating the production of large quantities of therapeutic DNA required to treat patients in need New data published in Nature Communications supports the benefits of this technology...

WuXi Advanced Therapies Testing Facility To Receive EMA GMP Certificate for New Philadelphia Facility

Jan 7, 2022

January 07, 2022 – Philadelphia. WuXi Advanced Therapies (WuXi ATU) announced it has successfully completed a remote European Medicines Agency (EMA) inspection for its advanced therapies testing facility at 400 Rouse Boulevard in its Philadelphia Navy Yard Campus, and...